vandetanib
vandetanib: 3 clinical trials tracked.
vandetanib evidence translation
What we can confirm
3 tracked trials
What it means
What to watch
Prepared research question
What is verified about vandetanib, and what remains unknown?
Traceable citations · Unknowns marked
See linked entities and source evidence1 indications · 2 study sponsors
Related indications
Clinical Trial Registry Records (3)
A Multicenter, Randomized, Open-label, Phase 3 Trial Comparing Selpercatinib to Physicians Choice of Cabozantinib or Vandetanib in Patients With Progressive, Advanced, Kinase Inhibitor Naïve, RET-Mutant Medullary Thyroid Cancer (LIBRETTO-531)
Primary endpoint: Progression Free Survival (PFS) by Blinded Independent Central Review (BICR)
An International, Randomised, Double-Blind, Two-Arm Study To Evaluate The Safety And Efficacy Of Vandetanib 150 And 300mg/Day In Patients With Unresectable Locally Advanced Or Metastatic Medullary Thyroid Carcinoma With Progressive Or Symptomatic Disease
Primary endpoint: Overall Response Rate (ORR) for Vandetanib 150 and 300mg With Responses Determined by the Investigator
A Randomized,Int.,Open-Label Phase III Study to Assess the Effect of a Patient Outreach Program on the Percentage of Time Patients With Locally Advanced or Metastatic MTC Experience Grade 2 or Higher AEs in the First 12 Months of Treatment With Vandetanib
Primary endpoint: Percentage of Time a Patient Experienced at Least 1 AE of CTCAE Grade >=2 in First 12 Months of Receiving Vandetanib in Patients Who Participated in Patient Outreach Program.